NewAmsterdam Pharma: Futurum sells 50,246 shares
The reported same-day sale was made under Futurum B.V.’s Rule 10b5-1 plan, adopted March 31, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
NewAmsterdam Pharma Co N.V. reported that Futurum B.V., through NAP PoolCo B.V. for the benefit of Chief Scientific Officer and director Johannes Jacob Pieter Kastelein, exercised options for 50,246 ordinary shares on September 30, 2026, at an option exercise price of EUR 1.16392, then sold the same 50,246 shares at a weighted average price of $25.03. The shares were sold in multiple transactions at $25.00 to $25.10 per share under a Rule 10b5-1 trading plan Futurum adopted on March 31, 2026.
After the exercise, Futurum held 344,983 options expiring July 6, 2031. Kastelein also reported a separate direct holding of 53,500 ordinary shares, including 48,166 shares subject to restricted stock unit awards that remain subject to vesting.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
4 txns
Insider
Kastelein Johannes Jacob Pieter
Role
Chief Scientific Officer
Sold
50,246 shs ($1.26M)
Approx. gross sale proceeds
$1.26M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option (right to buy) F1, F5, F6 | 50,246 | $0.00 | $0.00 |
| Exercise | Ordinary Shares F1, F2 | 50,246 | -- | -- |
| Sale | Ordinary Shares F3, F2 | 50,246 | $25.03 | $1.26M |
| holding | Ordinary Shares F4 | -- | -- | -- |
Holdings After Transaction:
Option (right to buy) — 344,983 contracts (Indirect, See footnote);
Ordinary Shares — 69,302 shares (Indirect, See footnotes);
Ordinary Shares — 53,500 shares (Direct)
Footnotes (6)
- F1. The exercise price of the option is EUR 1.16392.
- F2. These Ordinary Shares are held by Futurum B.V. ("Futurum") through NAP PoolCo B.V. ("PoolCo") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum.
- F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.10 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- F4. Includes 48,166 ordinary shares subject to restricted stock unit awards that remain subject to vesting.
- F5. The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
- F6. The option was granted to and is held by Futurum through NAP PoolCo B.V. ("PoolCo") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the Issuer.
Key Figures
Ordinary shares acquired on option exercise: 50,246 ordinary shares
Option exercise price: EUR 1.16392
Ordinary shares sold: 50,246 ordinary shares
+3 more
6 metrics
Ordinary shares acquired on option exercise
50,246 ordinary shares
September 30, 2026
Option exercise price
EUR 1.16392
Options exercised September 30, 2026
Ordinary shares sold
50,246 ordinary shares
September 30, 2026
Weighted average sale price
$25.03 per share
Shares sold September 30, 2026
Options held after exercise
344,983 options
Expiration date: July 6, 2031
Direct ordinary shares held
53,500 ordinary shares
Includes 48,166 shares subject to restricted stock unit awards that remain subject to vesting
Key Terms
Rule 10b5-1 trading plan, weighted average price, restricted stock unit awards, exercise price
4 terms
Rule 10b5-1 trading plan regulatory
"pursuant to a Rule 10b5-1 trading plan adopted by Futurum B.V."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
restricted stock unit awards financial
"shares subject to restricted stock unit awards that remain subject to vesting"
Restricted stock unit awards are company promises to deliver a specific number of shares to employees or service providers in the future once conditions—such as staying with the company for a set time or meeting performance targets—are met. They matter to investors because when the promises convert into actual shares they increase the total share count and can reduce earnings per share, while also aligning recipients’ interests with stock performance much like deferred pay that turns into ownership if goals are met.
exercise price financial
"The exercise price of the option is EUR 1.16392."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What option exercise and remaining option details were reported for NAMS?
Futurum exercised options for 50,246 ordinary shares at an exercise price of EUR 1.16392. Following the exercise, it held 344,983 options expiring July 6, 2031.
AI-generated analysis. How Rhea-AI works. Not financial advice.
